This care card's answer
The plan and the use both matter.
As of September 26, 2026, Medicare's usual prescription-drug insurance, Part D, still did not pay for medicines prescribed to help with weight loss.
For another accepted medical use, the same medicine may qualify for Part D payment when the plan's rules permit it.
There is a separate temporary Medicare programme.
As checked on September 26, 2026, Medicare's temporary GLP-1 Bridge programme offered some weight-loss medicines to eligible patients for $50 a month.
Semaglutide and tirzepatide are examples of GLP-1 medicines, which imitate a signal the body makes naturally to influence hunger and blood sugar.
The Bridge operates outside the usual Part D payment system, starting on July 1, 2026, and ending on December 31, 2027.
Your monthly $50 Bridge payment is excluded when adding up your spending toward the annual Part D limit for covered medicines. The Bridge gives no extra help with that payment to people on low incomes.
Eligibility involves the patient's health, age, plan and prior treatment, so enrolment in Medicare alone is not enough.
Ask the insurer about your exact plan.
- Does my plan cover this product for the use the clinician is prescribing it for?
- What approval steps or records does the plan require?
- What amount would I pay at the pharmacy?
- Does the online visit have a separate charge?
- What happens if coverage is denied?
Take this to the conversation
Can you confirm coverage and my own cost for this product and treatment use before it is filled?
Ask for the answer in plain words. Keep it with your visit notes.
Notes behind this answer
- Federal Register: the ordinary coverage exclusion
The final rule kept the usual Part D restriction on paying for weight-loss medicines.
- Medicare agency: how the temporary Bridge works
Read how the temporary programme works and what the patient pays each month.
- Medicare agency: Bridge eligibility and covered products
The full criteria matter; this card does not decide anyone's eligibility.